AMGN: Amgen Inc. - Summary | Jitta
Jitta Wealth
NEW
Log in
Sign up
×
Log in

Amgen Inc.

NASDAQ:AMGN

SummaryFactSheetFinancial
Price
$329.09
Loss Chance
42.5%
6.24JITTA SCORE
34.80%Over Jitta Line
Jitta Ranking
Biotechnology
17 / 282
Health Care
61 / 716
United States
?
686 / 4,224
Grow your money with Jitta Ranking. See details.
HISTORICAL JITTA SCORE
Related
Aurinia Pharmaceuticals
NASDAQ:AUPH
5.85
$15.14
39.46%
Aurinia Pharmaceuticals
NASDAQ:AUPH
5.85
$15.14
39.46%
Compugen Ltd.
NASDAQ:CGEN
4.58
$2.86
54.88%
Exelixis
NASDAQ:EXEL
6.77
$46.21
28.54%
Halozyme Therapeutics
NASDAQ:HALO
6.45
$65.19
56.59%
Jitta Factors
Growth Opportunity (57)
Recent Business Performance (71)
Financial Strength (65)
Return to Shareholders (85)
Competitive Advantage (75)
Jitta Signs
Revenue and EarningConsistent
Recent Business PerformanceEarning Growth Last Year
Return on EquityConsistently High
Dividend PayoutIncreasing Every Year
CapExVery Low
Interest Coverage RatioGood
SG&A to SalesDecreasing
Cash Conversion CycleMore than 120 days
Key Stats
Jitta Score
Jitta Line
6.24
34.80%
2.22
179.22%
3.06
149.57%
Biotechnology
5.85
39.46%
5.85
39.46%
4.58
54.88%
COMPANY DESCRIPTION
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company’s principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is headquartered in Thousand Oaks, California.
www.amgen.com
About UsCareersHelp CenterLibraryTermsPrivacyContact UsPress

Jitta Dot Com Co., Ltd. is the owner of the copyright of JITTA SCORE, JITTA LINE, JITTA SIGNS, JITTA FACTORS, JITTA LOSS CHANCE and JITTA RANKING. By accessing or using Jitta, you agree to comply with our Terms of Use and agree not to redistribute the information.

All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Any historical returns, backtest statistics or probability projections may not reflect future performance. Neither Jitta nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.

Fundamental data of companies, historical data, daily updates, financial statements, dividend data and index data are provided by S&P Global Market Intelligence. All stock prices are updated at the end of the day.